Skip to main content
Last updated: 6 February 2012

Update on Pip breast implants

Following further media coverage of PIP breast impants over the weekend, the ACRRM President, Professor Richard Murray, has provided the following information, based on advice from the Australian Chief Medical Officer, Professor Chris Baggoley.

There is no evidence that PIP implant should be treated differently to other brands of implants at this stage. Key points for doctors counselling patients:

  • There is no evidence of a link to cancer, including the rare anaplastic large cell lympoma.
  • There is no evidence of a higher rate of rupture or leakage compared to other brands of silicone implants. Around 10% of all types of implants rupture within 10 years of implantation.
  • TGA tests on PIP implant stocks show that the tensile strength of device meets international standards and that the gel is not cytotoxic.
  • There is a continuing program of testing among regulatory agencies internationally and more information may come to light.
  • There is no need for routine removal of PIP implants.Clinical issues (symptoms, tenderness, lumpiness, deflation, nodes etc) should be managed in consultation with surgical colleagues as would be usual for all breast implants.

Work on development of clinical guidelines continues and further advice will follow.